Adjuvo: adjuvant mitotane in patients with AC and low-intermediate risk of recurrence post-surgery

Jen-Jane Liu, MD, Oregon Health and Science University, Portland, OR, discusses the Adjuvo trial investigating mitotane in patients with adrenocortical carcinoma with low-intermediate risk of recurrence following surgery. The trial did not meet the primary endpoint of showing a benefit to adjuvant therapy in this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.